Breaking News
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
March 20, 2018 - ECG Patch Ups At-Home Afib Diagnosis in mSToPS Trial
Trial finds blood-plasma infusions for Alzheimer’s safe, promising

Trial finds blood-plasma infusions for Alzheimer’s safe, promising

image_pdfDownload PDFimage_print
PET scan of a human brain with Alzheimer’s disease. Credit: public domain

Stanford University School of Medicine investigators have reported success in an early-phase clinical trial examining the safety, tolerability and feasibility of administering infusions of blood plasma from young donors to participants with mild to moderate Alzheimer’s disease. There were also some signs suggesting improvements in participants’ conditions.

Results from the PLASMA trial, short for Plasma for Alzheimer’s Symptom Amelioration, will be presented Nov. 4 at the 10th annual Clinical Trial on Alzheimer’s Disease conference in Boston by Sharon Sha, MD, a clinical associate professor of neurology and neurological sciences at Stanford and the trial’s principal investigator.

Sha noted that the finding of safety wasn’t surprising, given that blood-plasma infusions have long been in widespread use for other indications and are considered extremely safe. More surprising, she said, were hints of recipients’ improvement on tests of functional ability: the capacity to perform basic tasks essential to independent daily life, such as remembering to take medications and being able to pay bills and prepare one’s own meals.

The PLASMA trial was designed to test a hypothesis advanced by Tony Wyss-Coray, PhD, Stanford professor of neurology and neurological sciences and a senior research career scientist at the Veterans Affairs Palo Alto Health Care System, whose research has shown that factors in the blood of young mice can rejuvenate the brain tissue and improve cognitive performance in old mice.

Larger studies needed

Sha, the clinical core co-leader of the Stanford Alzheimer’s Disease Research Center and the medical director of the Stanford Neuroscience Clinical Trials Group, cautioned that these assessments were based on caregiver reports and that the number of participants in the study—18—was small. Further studies on larger numbers of participants would be necessary before conclusions about efficacy could be reached, Sha said.

The trial took place at Stanford Hospital and was sponsored by Alkahest, a privately held biotechnology company headquartered in San Carlos, California. Alkahest holds intellectual property associated with the treatment regimen. Wyss-Coray, a co-founder of the company and chair of its scientific advisory board, continues to work full-time at Stanford. He was not involved in the clinical study.

The trial proceeded in two stages. In the first stage, nine participants with mild to moderate Alzheimer’s disease were given four weekly infusions either of plasma—the liquid, cell-free part of blood—obtained from donors 18-30 years old, or of placebo (a saline solution). Neither the participants nor those administering the infusions knew which of the two infusions any given participant was getting. Then, after a six-week “washout” period, the regimens were reversed: Those initially receiving plasma got four weekly infusions of placebo, and vice versa.

“Those participants served as their own controls,” said Sha.

Multiple tests and questionnaires to ascertain mood, cognition and functional ability of the participants were administered to either participants or their caregivers before and after the first four-week infusion period, and again before and after the second four-week infusion period.

The total time elapsing between a participant’s first and final visits, including a preliminary screening and a final visit, approached six months. The participants needed to make nearly a dozen round trips to Stanford, accompanied by a caregiver. So, to reduce the travel burden, the investigators decided to modify the design for their next group of nine participants.

These newcomers all received young-donor plasma infusions, and they and their caregivers, as well as the administrators, all knew it. This change cut the time between the first and final visits to 10-12 weeks for the second group of participants, and required commensurately fewer trips. These participants, like the first group, received the full battery of mood, cognition and functional-ability assessments.

Only a single, minor instance of a trial-related adverse event—excessive itching—occurred. Sha said this wasn’t entirely unanticipated, as it can arise as a side effect of the infusion of any blood product. Another participant had a stroke, but this was considered unrelated to the treatment; the participant had received only four infusions of saline and, furthermore, had suffered the stroke at the end of the ensuing washout period, during which no infusions of any kind were administered.

Improvements in functional ability

An analysis of assessments once all participants had been treated showed no significant changes in participants’ mood or their performance on tests of cognition involving tasks such as memorizing lists or recalling recent events, Sha said. These kinds of changes are typically observed only in clinical trials whose durations exceed one year, she added, so the absence of an effect here wasn’t particularly unanticipated.

But on two of three different assessments of functional ability, participants showed statistically significant improvement—this, despite the trial’s small size.

“That was surprising, to me,” said Sha. “The trial wasn’t powered to show efficacy.”

At first, the investigators suspected that the report of improvements in functional ability might have been driven by the second group of participants, who along with their caregivers and the investigators themselves knew they were getting plasma; this could perhaps predispose caregivers to optimistic reporting. But examination of the data indicated that, to the contrary, it was the first group of participants—who had no idea whether they were getting plasma or placebo—who showed the most improvement in functional ability after receiving plasma infusions.

“Our enthusiasm concerning these findings needs to be tempered by the fact that this was a small trial,” Sha said. “But these results certainly warrant further study.”

Alkahest has stated in a news release that based on the safety profile and signals of efficacy seen in the PLASMA trial, it is planning to advance the clinical development of a next-generation, proprietary plasma-derived product for the treatment of mild to moderate Alzheimer’s disease.

“I’m excited to see that giving repeated infusions of plasma to elderly people with Alzheimer’s disease is safe and that we can move forward to larger studies,” Wyss-Coray said. “But I’m also realistic enough to know that it is very easy to cure diseases in small animals and a million times more difficult in humans.”

Explore further:
Positive results from Alzheimer’s drug in Phase 1 clinical trial extension

Provided by:
Stanford University Medical Center

Tagged with:

About author

Related Articles